Analysts who follow BioXcel Therapeutics Inc (BTAI) on average expect it to add 145.61% over the next twelve months. Those same analysts give the stock an average rating of Buy. That average rating earns BTAI an Analyst Ranking of 26, which means it ranks higher than 26 of stocks, based on data compiled by InvestorsObserver.
Wall Street analysts are rating BTAI a Buy today. Find out what this means to you and get the rest of the rankings on BTAI!